Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 4Carcinoma, Transitional Cell 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 22Cisplatin 17Surveys and Questionnaires 8Radiotherapy 8Carboplatin 8Radiotherapy, Intensity-Modulated 7Cetuximab 7Paclitaxel 6Nivolumab 6Drug Therapy 6Radiation 4Fluorouracil 4Taxes 3Docetaxel 3selpercatinib 2dostarlimab 2Yoga 2Surgical Procedures, Operative 2Standard of Care 2Radiosurgery 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Chemoradiotherapy 2Blood Specimen Collection 2ALX148 2veliparib 1tisotumab vedotin 1tislelizumab 1palbociclib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Head and Neck Neoplasms × enfortumab vedotin × Clear all
NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡